Principles of the activin receptor signaling pathway and its inhibition

This review captures the anabolic and stimulatory effects observed with inhibition of the transforming growth factor beta superfamily in muscle, blood, and bone. New medicinal substances that rectify activin, myostatin, and growth differentiation factor 11 signaling give hope to the many whose lives are affected by deterioration of these tissues. The review first covers the origin, structure, and common pathway of activins, myostatin, and growth differentiation factor 11 along with the pharmacodynamics of the new class of molecules designed to oppose the activin receptor signaling pathway. Current terminology surrounding this new class of molecules is inconsistent and does not infer functionality. Adopting inhibitors of the activin receptor signaling pathway (IASPs) as a generic term is proposed because it encapsulates the molecular mechanisms along the pathway trajectory. To conclude, a pragmatic classification of IASPs is presented that integrates functionality and side effects based on the data available from animals and humans. This provides researchers and clinicians with a tool to tailor IASPs therapy according to the need of projects or patients and with respect to side effects.

Automated summary

This article discusses the potential anabolic and stimulatory effects of inhibiting the transforming growth factor beta superfamily in muscle, blood, and bone. New therapeutic substances targeting activin, myostatin, and growth differentiation factor 11 signaling pathways offer hope for tissue deterioration. Additionally, a proposed classification of activin receptor signaling pathway inhibitors (IASPs) aims to provide a tool for researchers and clinicians to tailor therapy based on functionality and side effects.